15034 Federal Register / Vol. 80, No. 54 / Friday, March 20, 2015 / Notices 

The publication of this notice opens 

a period for public comment on the 

proposed Consent Decree. Comments 

should be addressed to the Assistant 

Attorney General, Environment and 

Natural Resources Division, and should 

refer to United States and the State of 

Indiana v. Exide Technologies, D.J. Ref. 

No. 90–5–2–1–11003. All comments 

must be submitted no later than thirty 

(30) days after the publication date of 

this notice. Comments may be 

submitted either by email or by mail: 

To submit 

comments: Send them to: 

By email ....... pubcomment-ees.enrd@

usdoj.gov. 

By mail ......... Assistant Attorney General 

U.S. DOJ—ENRD 

P.O. Box 7611 

Washington, D.C. 20044– 

7611. 

During the public comment period, 

the Consent Decree may be examined 

and downloaded at this Justice 

Department Web site: http://

www.usdoj.gov/enrd/Consent_

Decrees.html. We will provide a paper 

copy of the Consent Decree upon 

written request and payment of 

reproduction costs (at 25 cents per 

page). Please mail your request and a 

check or money order payable to the 

United States Treasury to: Consent 

Decree Library, U.S. DOJ—ENRD, P.O. 

Box 7611, Washington, DC 20044–7611. 

The cost for a paper copy of the 

Consent Decree is $8.25. 

Randall M. Stone, 

Acting Assistant Section Chief, 

Environmental Enforcement Section, 

Environment and Natural Resources Division. 

[FR Doc. 2015–06369 Filed 3–19–15; 8:45 am] 

BILLING CODE 4410–15–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–410] 

Controlled Substances: 2015 Proposed 

Aggregate Production Quotas for 

Three Temporarily Controlled 

Synthetic Cannabinoids 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: Three synthetic cannabinoids: 

N-(1-amino-3-methyl-1-oxobutan-2-yl)- 

1-(cyclohexylmethyl)-1H-indazole-3- 

carboxamide (AB-CHMINACA), N-(1- 

amino-3-methyl-1-oxobutan-2-yl)-1- 

pentyl-1H-indazole-3-carboxamide (ABPINACA), and [1-(5-fluoropentyl)-1Hindazol-3-yl](naphthalen-1- 

yl)methanone (THJ-2201) were 

temporarily placed in schedule I of the 

Controlled Substances Act by a final 

order published by the Drug 

Enforcement Administration on January 

30, 2015 (80 FR 5042). This means that 

any person that wishes to manufacture 

AB-CHMINACA, AB-PINACA, or THJ2201 after January 30, 2015, must be 

registered with the Drug Enforcement 

Administration and have obtained a 

manufacturing quota pursuant to 21 

CFR part 1303. 

The Drug Enforcement 

Administration cannot issue individual 

manufacturing quotas for ABCHMINACA, AB-PINACA, or THJ-2201 

until it establishes aggregate production 

quotas. Therefore, this notice proposes 

the 2015 aggregate production quotas for 

AB-CHMINACA, AB-PINACA, and THJ2201. 

DATES: Interested persons may file 

written comments on this notice in 

accordance with 21 CFR 1303.11(c). 

Electronic comments must be 

submitted, and written comments must 

be postmarked, on or before April 20, 

2015. Commenters should be aware that 

the electronic Federal Docket 

Management System will not accept 

comments after 11:59 p.m. Eastern Time 

on the last day of the comment period. 

Based on comments received in 

response to this Notice, the 

Administrator may hold a public 

hearing on one or more issues raised. In 

the event the Administrator decides in 

her sole discretion to hold such a 

hearing, the Administrator will publish 

a notice of any such hearing in the 

Federal Register. After consideration of 

any comments and after a hearing, if one 

is held, the Administrator will publish 

in the Federal Register a final order 

establishing the 2015 aggregate 

production quotas for AB-CHMINACA, 

AB-PINACA, and THJ-2201. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–410’’ on all correspondence, 

including any attachments. The Drug 

Enforcement Administration encourages 

that all comments be submitted 

electronically through the Federal 

eRulemaking Portal which provides the 

ability to type short comments directly 

into the comment field on the Web page 

or attach a file for lengthier comments. 

Please go to http://www.regulations.gov 

and follow the online instructions at 

that site for submitting comments. Upon 

completion of your submission you will 

receive a Comment Tracking Number for 

your comment. Please be aware that 

submitted comments are not 

instantaneously available for public 

view on Regulations.gov. If you have 

received a Comment Tracking Number, 

your comment has been successfully 

submitted and there is no need to 

resubmit the same comment. Paper 

comments that duplicate an electronic 

submission are not necessary and are 

discouraged. Should you wish to mail a 

paper comment in lieu of an electronic 

comment, it should be sent via regular 

or express mail to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODXL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

FOR FURTHER INFORMATION CONTACT: 

Imelda L. Paredes, Office of Diversion 

Control, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, Virginia 

22152; Telephone: (202) 598–6812. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received in response to this docket are 

considered part of the public record and 

will be made available for public 

inspection online at http://

www.regulations.gov. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

The Freedom of Information Act 

applies to all comments received. If you 

want to submit personal identifying 

information (such as your name, 

address, etc.) as part of your comment, 

but do not want it to be posted online 

or made available in the public docket, 

you must include the phrase 

‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want publicly available in 

the first paragraph of your comment and 

identify what information you want 

redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be made 

publicly available, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Comments containing personal 

identifying information or confidential 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 54 / Friday, March 20, 2015 / Notices 15035 

business information identified as 

directed above will be made publicly 

available in redacted form. 

An electronic copy of this document 

is available at http://

www.regulations.gov for easy reference. 

If you wish to personally inspect the 

comments and materials received, these 

materials will be available for public 

inspection by appointment. To arrange 

a viewing, please see the FOR FURTHER

INFORMATION CONTACT paragraph above. 

Legal Authority and Background 

Section 306 of the Controlled 

Substances Act (CSA), 21 U.S.C. 826, 

requires that the Attorney General 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II 

each year. This responsibility has been 

delegated to the Administrator of the 

Drug Enforcement Administration 

(DEA). 28 CFR 0.100. 

The DEA established the 2015 

aggregate production quotas for 

substances in schedules I and II on 

September 8, 2014 (79 FR 53216). 

Subsequently, on December 19, 2014, 

DEA published in the Federal Register 

a notice of intent to temporarily place 3 

synthetic cannabinoids: N-(1-amino-3- 

methyl-1-oxobutan-2-yl)-1- 

(cyclohexylmethyl)-1H-indazole-3- 

carboxamide (AB-CHMINACA), N-(1- 

amino-3-methyl-1-oxobutan-2-yl)-1- 

pentyl-1H-indazole-3-carboxamide (ABPINACA), and [1-(5-fluoropentyl)-1Hindazol-3-yl](naphthalen-1- 

yl)methanone (THJ-2201) into schedule 

I of the CSA (79 FR 75767). On January 

30, 2015, the DEA published in the 

Federal Register a final order to 

temporarily place these three synthetic 

cannabinoids in schedule I of the CSA 

(80 FR 5042), making all regulatory 

controls pertaining to schedule I 

controlled substances applicable to the 

manufacture of these three synthetic 

cannabinoids, including the 

requirement to establish an aggregate 

production quota pursuant to 21 U.S.C. 

826 and 21 CFR part 1303. 

AB-CHMINACA, AB-PINACA, and 

THJ-2201 were non-controlled 

substances when the aggregate 

production quotas for schedule I and II 

substances were established. Therefore 

no aggregate production quotas for ABCHMINACA, AB-PINACA, and THJ2201 were established at that time. 

In determining the 2015 aggregate 

production quotas of these three 

synthetic cannabinoids, the 

Administrator considered the following 

factors in accordance with 21 U.S.C. 

826(a) and 21 CFR 1303.11(b): (1) Total 

net disposal of the class by all 

manufacturers during the current and 2 

preceding years; (2) trends in the 

national rate of net disposal of the class; 

(3) total estimated inventories of the 

basic class and of all substances 

manufactured from the class, and trends 

in inventory accumulation; (4) projected 

demand for each class as indicated by 

procurement quotas requested pursuant 

to 21 CFR 1303.12; and (5) other factors 

affecting medical, scientific, research, 

and industrial needs of the United 

States and lawful export requirements, 

as the Administrator finds relevant. 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. 

The Administrator, therefore, 

proposes that the annual 2015 aggregate 

production quotas for the following 

temporarily controlled schedule I 

controlled substances, expressed in 

grams of anhydrous acid or base, be 

established as follows: 

Basic class—schedule I 

Proposed 

2015 quota 

(g) 

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) .................................... 15 

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) .............................................................. 15 

[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) ...................................................................................... 15 

Dated: March 12, 2015. 

Michele M. Leonhart, 

Administrator. 

[FR Doc. 2015–06456 Filed 3–19–15; 8:45 am] 

BILLING CODE 4410–09–P 

MORRIS K. UDALL AND STEWART L. 

UDALL FOUNDATION 

Sunshine Act Meetings 

TIME AND DATE: 9:00 a.m. to 4:00 p.m., 

Thursday, April 16, 2015. 

PLACE: The offices of the Morris K. 

Udall and Stewart L. Udall Foundation, 

130 South Scott Avenue, Tucson, AZ 

85701. 

STATUS: This meeting of the Board of 

Trustees will be open to the public. 

MATTERS TO BE CONSIDERED: (1) Chair’s 

Remarks; (2) Executive Director’s 

Remarks; (3) Overview of Trustee 

Responsibilities; (4) Board Officers & 

Committee Elections; (5) Consent 

Agenda Approval, including program 

reports of the Education Programs, U.S. 

Institute for Environmental Conflict 

Resolution, and Udall Center for Studies 

in Public Policy/Native Nations Institute 

for Leadership, Management, and 

Policy/Udall Archives, and resolutions 

related to the Operating Procedures of 

the Board of Trustees and the Parks in 

Focus Fund, Inc. (6) Financial and 

Internal Controls Update; (7) Ethics 

Briefing; (8) Program Panel & 

Discussion; and (9) Appropriations 

Update. 

CONTACT PERSON FOR MORE INFORMATION: 

Philip J. Lemanski, Executive Director, 

130 South Scott Avenue, Tucson, AZ 

85701, (520) 901–8500. 

Dated: March 16, 2015. 

Philip J. Lemanski, 

Executive Director, Morris K. Udall and 

Stewart L. Udall Foundation, and Federal 

Register Liaison Officer. 

[FR Doc. 2015–06556 Filed 3–18–15; 4:15 pm] 

BILLING CODE 6820–FN–P 

NUCLEAR REGULATORY 

COMMISSION 

[NRC–2015–0001] 

Sunshine Act Meetings 

DATES: March 23, 30, April 6, 13, 20, 27, 

2015. 

PLACE: Commissioners’ Conference 

Room, 11555 Rockville Pike, Rockville, 

Maryland. 

STATUS: Public and Closed. 

Week of March 23, 2015—Tentative 

Thursday, March 26, 2015 

9:30 a.m. Briefing on Security Issues 

(Closed—Ex. 1) 

1:30 p.m. Briefing on Security Issues 

(Closed—Ex. 1) 

Friday, March 27, 2015 

9:30 a.m. Briefing on Threat 

Environment Assessment (Closed— 

Ex. 1) 

mstockstill on DSK4VPTVN1PROD with NOTICES